CBPd-171 — IND submission
2026
IND-ready Selective CBP Degrader 2026Source filing
FHTX biotech catalysts & pipeline
FOGHORN THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
Selective ARID1B degrader — Initial data
2026
• Program advancing towards in vivo proof-of-concept in 2026Source filing
Selective EP300 degrader — IND submission
2026
Phase 1 Monotherapy DataFHD-909* (LY4050784) (Selective SMARCA2 Inhibitor) 2026IND / Phase 1 InitiationSelective CBP Degrader 2026IND / Phase 1 InitiationSelective EP300 Degrader ConfidentialIND / Phase 1 InitiationSelective SMARCA2 Degrader* ConfidentialTarget Disclosure and INDLilly Target #2** Q4 2025Program UpdateSelective ARID1B Degrader * 50/50 U.S. economic split, ex-U.S. royalties. ** Pending Lilly decision to proceed, 50/50 U.S. economic split, ex-U.S. royalties. ConfidentialSource filing
CBPd-171 — IND submission
2027
Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027Source filing
novel oral small molecule — IND submission
2027
Accelerating a novel oral small molecule in immunology and inflammation toward IND in 2027Source filing
Selective EP300 degrader — IND submission
2027
• IND targeted in 2027 , with a focus in MM and DLBCL.Source filing
Undisclosed — IND submission
2027
Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027Source filing
undisclosed program in immunology and inflammation — IND submission
2027
We are targeting an IND in 2027 for this asset, underscoring the breadth of our platform and demonstrating its potential across multiple therapeutic areas.Source filing